Dataset Information

Enhanced competition at the nano-bio interface enables comprehensive characterization of protein corona dynamics and deep coverage of proteomes

ABSTRACT: We demonstrate the importance of the protein to NP-surface ratio (P/NP) and model protein corona formation dynamics, which determine the competition between proteins for binding.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Theo Platt

LAB HEAD: Daniel Hornburg

PROVIDER: PXD030327 | Pride | 2022-09-02

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	EXP21053_10plates_libfree_relaxed.pg_matrix.tsv	Tabular
	EXP21053_2021ms0297X10_A_BB2_1_1884.d.zip	Other
	EXP21053_2021ms0297X11_A_BC2_1_1896.d.zip	Other
	EXP21053_2021ms0297X12_A_BD2_1_1906.d.zip	Other
	EXP21053_2021ms0297X13_A_BE2_1_1918.d.zip	Other

Items per page:

1 - 5 of 825

Publications

Enhanced Competition at the Nano-Bio Interface Enables Comprehensive Characterization of Protein Corona Dynamics and Deep Coverage of Proteomes.

Ferdosi Shadi S Stukalov Alexey A Hasan Moaraj M Tangeysh Behzad B Brown Tristan R TR Wang Tianyu T Elgierari Eltaher M EM Zhao Xiaoyan X Huang Yingxiang Y Alavi Amir A Lee-McMullen Brittany B Chu Jessica J Figa Mike M Tao Wei W Wang Jian J Goldberg Martin M O'Brien Evan S ES Xia Hongwei H Stolarczyk Craig C Weissleder Ralph R Farias Vivek V Batzoglou Serafim S Siddiqui Asim A Farokhzad Omid C OC Hornburg Daniel D

Advanced materials (Deerfield Beach, Fla.) 20220920 44

Introducing engineered nanoparticles (NPs) into a biofluid such as blood plasma leads to the formation of a selective and reproducible protein corona at the particle-protein interface, driven by the relationship between protein-NP affinity and protein abundance. This enables scalable systems that leverage protein-nano interactions to overcome current limitations of deep plasma proteomics in large cohorts. Here the importance of the protein to NP-surface ratio (P/NP) is demonstrated and protein c ...[more]

PMID: 35986672

Similar Datasets

Project description:Pancreatic ductal adenocarcinoma (PDAC) suffers from lack of an effective diagnostic method, limiting improvement in patient survival. Although the FDA-approved biomarker CA19-9 has been used for detection and surveillance of PDAC, its clinical utility is generally regarded to be limited due to its suboptimal diagnostic performance. Liquid chromatography-mass spectrometry (LC-MS) has emerged as a burgeoning technology in clinical proteomics, and identified a plethora of protein biomarker candidates for PDAC. Yet few if any has successfully transitioned into clinical practice. This translational standstill is owed partly to the limited considerations of practical needs and perspectives of clinical implementation in the course of a biomarker pipeline, such as demonstrating analytical validity of proposed biomarkers, which is critical to turning research-grade assays to clinical-grade tests. Here, we developed a fit-for-purpose multi-marker panel for PDAC diagnosis by consolidating analytically robust biomarkers as well as employing a relatively simple LC-MS method. In the discovery phase, we systematically collected putative biomarkers from both in-house proteomics data and the large volume of literature documenting PDAC biomarkers. In the verification phase, we developed a multiple-reaction monitoring (MRM)-MS-based proteomic assay using surrogate peptides that passed stringent analytical validation criteria. Given the intended use of our panel (i.e., primary screening), we adopted a high-throughput protocol including short gradient (<10 min) and simple sample preparation (no depletion or enrichment steps). To further facilitate clinical implementation, we performed verification of our panel on serum samples, which are usually the preferred biospecimen available in clinical settings. We developed a stacking ensemble model based on our final panel of 12 protein biomarkers combined with CA19-9, which showed improved diagnostic performance compared to using CA19-9 alone (AUC 0.919 and 0.830, respectively). A large-scale clinical validation study is underway to demonstrate the clinical validity of our panel.